Bernard Zinman

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 48

Top Topics

Left Ventricular

Cardiovascular Events

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Chang Ye, Jiajie Pu, Chang Ye, Alexandra Emery, Stewart B Harris, Sonja M Reichert, Ulagamadesan Venkatesan, Natalia McInnes, Caroline Kaercher Kramer, Bernard Zinman
A Glycemic Threshold Above Which the Improvement of β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Early Type 2 Diabetes: The Reversal of Glucotoxicity. Diabetes care (2024)
Chang Ye, Jiajie Pu, Alexandra Emery, Caroline Kaercher Kramer, Bernard Zinman
Concordance of A1C, Fasting Glucose, and Oral Glucose Tolerance Test Criteria for Defining Remission of Diabetes. Diabetes care (2023)
Chang Ye, Jiajie Pu, Alexandra Emery, Caroline K Kramer, Bernard Zinman
Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell function. Diabetes, obesity & metabolism (2023)
Sadia Mehmood, Chang Ye, Anthony J Hanley, Philip W Connelly, Mathew Sermer, Bernard Zinman, Chang Ye
Impact of the diagnosis of gestational diabetes on maternal physical activity after pregnancy. Diabetes, obesity & metabolism 26 (4) (2023)
Chang Ye, Jiajie Pu, Alexandra Emery, Caroline Kaercher Kramer, Bernard Zinman
Concordance of A1C, Fasting Glucose, and Oral Glucose Tolerance Test Criteria for Defining Remission of Diabetes. Diabetes care 46 (3) (2023)
Chang Ye, Jiajie Pu, Alexandra Emery, Caroline Kaercher Kramer, Bernard Zinman
Concordance of A1C, Fasting Glucose, and Oral Glucose Tolerance Test Criteria for Defining Remission of Diabetes. Diabetes care 46 (3) (2023)
Sadia Mehmood, Chang Ye, Anthony J Hanley, Philip W Connelly, Mathew Sermer, Bernard Zinman, Chang Ye
Impact of the diagnosis of gestational diabetes on maternal physical activity after pregnancy. Diabetes, obesity & metabolism 26 (4) (2023)
Sadia Mehmood, Chang Ye, Anthony J Hanley, Philip W Connelly, Mathew Sermer, Bernard Zinman, Chang Ye
Impact of the diagnosis of gestational diabetes on maternal physical activity after pregnancy. Diabetes, obesity & metabolism (2023)
John M Lachin, Ionut Bebu, Xiaoyu Gao, David M Nathan, Bernard Zinman, null null
Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes care 45 (10) (2022)
John M Lachin, Ionut Bebu, Xiaoyu Gao, David M Nathan, Bernard Zinman
Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448. Diabetes care 46 (1) (2022)
Denice S Feig, Bernard Zinman, Elizabeth Asztalos, Lois E Donovan, Prakesh S Shah, J Johanna Sanchez, George Tomlinson, Kellie E Murphy
Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin? Diabetes care 45 (7) (2022)
Sabine Kahl, Anne Pernille Ofstad, Bernard Zinman, Christoph Wanner, Elke Schueler, Naveed Sattar, Catherine M Viscoli, Michael Roden
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes, obesity & metabolism 24 (6) (2022)
Bruce A Perkins, Ionut Bebu, Xiaoyu Gao, Amy B Karger, Irl B Hirsch, Harsha Karanchi, Mark E Molitch, Bernard Zinman, John M Lachin, Ian H de Boer
Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes care 45 (3) (2022)
John M Lachin, Ionut Bebu, Xiaoyu Gao, David M Nathan, Bernard Zinman
Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448. Diabetes care 46 (1) (2022)
Chang Ye, Bernard Zinman
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future. Diabetes, obesity & metabolism (2021)
Chang Ye, Alexandra Emery, Chang Ye, Stewart B Harris, Sonja M Reichert, Natalia McInnes, Ulagamadesan Venkatesan, Kevin E Thorpe, Caroline Kaercher Kramer, Bernard Zinman
Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial. Diabetes, obesity & metabolism 23 (8) (2021)
Muthiah Vaduganathan, Catherine M Viscoli, Naveed Sattar, David H Fitchett, Anne Pernille Ofstad, Martina Brueckmann, Jyothis T George, Subodh Verma, Michaela Mattheus, Christoph Wanner, Bernard Zinman, Javed Butler
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. Diabetes, obesity & metabolism 23 (12) (2021)
Subodh Verma, C David Mazer, Catherine M Viscoli, Christoph Wanner, Anne Pernille Ofstad, Odd Erik Johansen, Isabella Zwiener, Jyothis T George, Javed Butler, Bernard Zinman
Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. Diabetes, obesity & metabolism 23 (5) (2021)
Kristin K Clemens, Mark Woodward, Bruce C Neal, Bernard Zinman
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. Diabetes care 43 (5) (2021)
Clare Arnott, Jing-Wei Li, Christopher P Cannon, Dick de Zeeuw, Brendon L Neuen, Hiddo J Lambers Heerspink, David M Charytan, Anubha Agarwal, Mark D Huffman, Gemma A Figtree, George L Bakris, Tara I-Hsin Chang, Kent Feng, Norman Rosenthal, Bernard Zinman, Meg J Jardine, Vlado Perkovic, Bruce C Neal, Kenneth W Mahaffey
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes, obesity & metabolism 23 (7) (2021)
Joao Pedro Ferreira, Catherine M Viscoli, Michaela Mattheus, Thomas Meinicke, Dominik Steubl, Christoph Wanner, Bernard Zinman
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes, obesity & metabolism 24 (1) (2021)
Zhila Semnani-Azad, Philip W Connelly, Richard P Bazinet, Ravi Retnakaran, David J A Jenkins, Stewart B Harris, Bernard Zinman, Anthony J Hanley
Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort. Diabetes care 44 (7) (2021)
Qiuhe Ji, Linong Ji, Yi-Ming Mu, Jiajun Zhao, Bernard Zinman, Christoph Wanner, Jyothis T George, Isabella Zwiener, Kohjiro Ueki, Koutaro Yokote, Wataru Ogawa, Odd Erik Johansen
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia. Diabetes, obesity & metabolism 23 (8) (2021)
Subodh Verma, Abhinav Sharma, Bernard Zinman, Anne Pernille Ofstad, David H Fitchett, Martina Brueckmann, Christoph Wanner, Isabella Zwiener, Jyothis T George, Silvio E Inzucchi, Javed Butler, C David Mazer
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes, obesity & metabolism 22 (7) (2020)
Subodh Verma, Darren K McGuire, Stephen C Bain, Deepak L Bhatt, Lawrence A Leiter, C David Mazer, Tea Monk Fries, Richard E Pratley, Søren Rasmussen, Hrvoje Vrazic, Bernard Zinman, John B Buse
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes, obesity & metabolism 22 (12) (2020)
Subodh Verma, Stephen C Bain, Julie Broe Honoré, Johannes F E Mann, Michael A Nauck, Richard E Pratley, Søren Rasmussen, Maria Sejersten Ripa, Bernard Zinman, John B Buse
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. Diabetes, obesity & metabolism 22 (11) (2020)
Christoph Wanner, Silvio E Inzucchi, Bernard Zinman, Audrey Koitka-Weber, Michaela Mattheus, Jyothis T George, Maximilian von Eynatten, Sibylle J Hauske, null null
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. Diabetes, obesity & metabolism 22 (12) (2020)
John B Buse, Stephen C Bain, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Richard E Pratley, Martin Linder, Tea Monk Fries, David D Ørsted, Bernard Zinman, null null
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes care 43 (7) (2020)
Vlado Perkovic, Robert Toto, Mark E Cooper, Johannes F E Mann, Julio Rosenstock, Darren K McGuire, Steven E Kahn, Nikolaus Marx, John H Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T George, Odd Erik Johansen, Christoph Wanner, null null
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes care 43 (8) (2020)
Ian J Neeland, Bjorn Eliasson, Takatoshi Kasai, Nikolaus Marx, Bernard Zinman, Catherine M Viscoli, Christoph Wanner, Isabella Zwiener, Brian S Wojeck, Henry K Yaggi, Odd Erik Johansen, null null
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes care 43 (12) (2020)
Subodh Verma, Qiuhe Ji, Deepak L Bhatt, C David Mazer, Mohammed Al-Omran, Silvio E Inzucchi, Christoph Wanner, Anne Pernille Ofstad, Isabella Zwiener, Jyothis T George, Bernard Zinman, David H Fitchett
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. Diabetes, obesity & metabolism 22 (7) (2020)
John M Lachin, David M Nathan, Bernard Zinman, Ionut Bebu
Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291-299. Diabetes 69 (7) (2020)
Ruth L Coleman, Alastair M Gray, Uli C Broedl Md, David H Fitchett, Jyothis T George, Hans J Woerle, Bernard Zinman, Rury R Holman
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels? Diabetes, obesity & metabolism 22 (7) (2020)
Mark A Espeland, Richard E Pratley, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Bernard Zinman, Nikolaus Marx, Darren K McGuire, Knut Robert Andersen, Michaela Mattheus, Annett Keller, Maria Weber, Odd Erik Johansen
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes, obesity & metabolism 23 (2) (2020)
Subodh Verma, Stephen C Bain, Tea Monk Fries, C David Mazer, Michael A Nauck, Richard E Pratley, Søren Rasmussen, Hans A Saevereid, Bernard Zinman, John B Buse
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes, obesity & metabolism 21 (7) (2019)
Catherine M Viscoli, Christoph Wanner, Uwe Hehnke, Isabella Zwiener, Stefan Kaspers, Douglas Clark, Jyothis T George, Bernard Zinman
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. Diabetes care 42 (4) (2019)
Ronald M Goldenberg, Jeremy D Gilbert, Irene M Hramiak, Vincent C Woo, Bernard Zinman
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes, obesity & metabolism 21 (10) (2019)
Kirstine Brown-Frandsen, Scott S Emerson, Darren K McGuire, Thomas R Pieber, Neil R Poulter, Richard E Pratley, Bernard Zinman, Mattis F Ranthe, Randi Grøn, Martin Lange, Alan C Moses, Petra Örsy, John B Buse, null null
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). Diabetes, obesity & metabolism 21 (6) (2019)
Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Bernard Zinman, Julio Rosenstock, Jyothis T George, Anna Passera, Sven Schnaidt, Odd Erik Johansen, null null
Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes care 42 (10) (2019)
Subodh Verma, C David Mazer, Deepak L Bhatt, Satish R Raj, Andrew T Yan, Atul Verma, Eleuterio Ferrannini, Gudrun Simons, Jisoo Lee, Bernard Zinman, Jyothis T George, David Fitchett
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. Diabetes care 42 (3) (2019)
Bernard Zinman, Vanita R Aroda, John B Buse, Bertrand Cariou, Stewart B Harris, Søren Tetens Hoff, Karen Boje Pedersen, Mads Jeppe Tarp-Johansen, Eiichi Araki, null null
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes care 42 (12) (2019)
Cornelis Cees J Tack, Stephan Jacob, Cyrus Desouza, Stephen C Bain, John B Buse, Michael A Nauck, John R Petrie, Neil R Poulter, Richard E Pratley, Helen Vanya B K Stegmann, Heidrun Bosch-Traberg, Elena Startseva, Bernard Zinman, null null
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes, obesity & metabolism 21 (11) (2019)
Richard F Pollock, Simon R Heller, Thomas R Pieber, Vincent Woo, Jens Gundgaard, Nino Hallén, Maria Luckevich, Deniz Tutkunkardas, Bernard Zinman, null null
Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, obesity & metabolism 21 (7) (2019)
Richard E Pratley, Scott S Emerson, Edward Franek, Matthew P Gilbert, Steven P Marso, Darren K McGuire, Thomas R Pieber, Bernard Zinman, Charlotte T Hansen, Melissa V Hansen, Thomas Mark, Alan C Moses, John B Buse, null null
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes, obesity & metabolism 21 (7) (2019)
J Hans DeVries, Timothy S Bailey, Anuj Bhargava, Gregg Gerety, Janusz Gumprecht, Simon R Heller, Wendy Lane, Carol H Wysham, Bernard Zinman, Britta A Bak, Elise Hachmann-Nielsen, Athena Philis-Tsimikas
Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. Diabetes, obesity & metabolism 21 (3) (2018)
Julio Rosenstock, Jan Marquard, Lori M B Laffel, Dietmar Neubacher, Stefan Kaspers, David Z I Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou, Bruce A Perkins
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes care 41 (12) (2018)
Chang Ye, Haysook Choi, Chang Ye, Caroline Kaercher Kramer, Bernard Zinman
Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetes. Diabetes, obesity & metabolism 20 (6) (2018)
Bernard Zinman, Steven P Marso, Erik Christiansen, Salvatore Calanna, Søren Rasmussen, John B Buse, null null
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes care 41 (8) (2018)